FDA Approves Myrbetriq to Treat Pediatric NDO
The US Food and Drug Administration (FDA) has expanded the indication for Mirabegron (Myrbetriq/Myrbetriq Granules) to treat neurogenic detrusor overactivity
Read moreThe US Food and Drug Administration (FDA) has expanded the indication for Mirabegron (Myrbetriq/Myrbetriq Granules) to treat neurogenic detrusor overactivity
Read moreA study led by UT Southwestern and Children's Health researchers defines parameters for the number of white blood cells that
Read moreMost people associate the menopause with hot flashes (also known as hot flushes); however there are many other potential symptoms
Read more